Quanterix lowered its 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million after second-quarter revenue of $32.9 million fell $3 million short of its own guidance amid broad market weakness and commercial execution challenges. The company also pushed its cash-flow breakeven target to 2027 and now expects to end 2026 with about $80 million in cash, down from a prior estimate of $100 million. On a pro forma basis including Akoya's pre-acquisition revenue, revenue declined 23% year over year, with Simoa revenue falling in the low teens and Spatial revenue declining as academic and government demand remained particularly weak. Quanterix completed its Akoya integration and achieved $85 million in annualized savings, helping lift non-GAAP gross margin to 47.9%. The company is restructuring its sales organization around product solutions and expects Simoa to recover more quickly than Spatial, while advancing its Alzheimer's diagnostics strategy with LucentAD Complete gaining coverage for qualifying Anthem members and targeting FDA approval for a blood-based biomarker test by late 2026.
Quanterix CorpQ2 revenue missed guidance and 2026 outlook cut, with cash-flow breakeven pushed to 2027.
